CNS Pharmaceuticals Inc (OQ:CNSP)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 2100 West Loop S Ste 900
HOUSTON TX 77027-3522
Tel: N/A
IR: See website
Key People
Business Overview
CNS Pharmaceuticals Inc. is a preclinical stage pharmaceutical company. The Company is focused on developing anticancer drug candidates for the treatment of brain and central nervous system tumors. The Company is focused on developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity. It results in the inhibition of DNA replication and repair, and Ribonucleic acid (RNA) and protein synthesis.
Financial Overview
For the three months ended 31 March 2020, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased from $212K to $2M. Higher net loss reflects Selling/General/Admin Expense increase from $147K to $1.4M (expense), Research and development increase from $48K to $613K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.01 to -$0.12.
Employees: 3 as of Mar 11, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $24.72M as of Jun 30, 2020
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$5.60M as of Jun 30, 2020
Net annual income (TTM): -$5.63M as of Jun 30, 2020
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: N/A
Shares outstanding: 16,450,234 as of May 15, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.